Retatrutide Weight Loss Results: 71 lbs Average in Phase 3

The first question everyone asks about a new obesity drug is: how much weight will I lose?

For retatrutide, the answer from Phase 3 clinical trials is: an average of 71.2 pounds. That number, announced in December 2025 from Eli Lilly's TRIUMPH-1 trial, is the highest average weight loss ever recorded in a Phase 3 obesity trial. By a significant margin.

The Headline Numbers

• Phase 3 (TRIUMPH-1, 2025): 71.2 lbs average weight loss (~30% body weight)
• Phase 2 (NEJM, 2023): 24.2% average body weight loss at highest dose (48 weeks)
• Competitor (Tirzepatide): ~52 lbs average (~22% body weight)
• Competitor (Semaglutide): ~34 lbs average (~15% body weight)

Phase 2 Data (NEJM, 2023)

The first major look at retatrutide's efficacy came from Phase 2 results published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity across multiple dose cohorts over 48 weeks:

Key observation from Phase 2: the weight loss curve had not plateaued at 48 weeks. Participants were still actively losing weight when the trial ended. This suggested Phase 3, with its longer duration, would show even larger totals — which it did.

Phase 3 Data (TRIUMPH-1, December 2025)

The TRIUMPH-1 results, announced December 2025, confirmed what Phase 2 had suggested. In a larger, longer, and more diverse patient population:

• Average weight loss: 71.2 lbs (~30% of body weight)
• All primary endpoints met
• All key secondary endpoints met
• Additional finding: significant reduction in osteoarthritis pain — not seen with other TRT drugs
• Seven additional TRIUMPH Phase 3 readouts expected in 2026

The osteoarthritis result is clinically significant in its own right. It suggests retatrutide's glucagon receptor component may have direct anti-inflammatory effects beyond those attributable to weight loss alone — a potentially separate therapeutic benefit.

Why the Results Are So Much Better

The progression from semaglutide to tirzepatide to retatrutide follows a clear pattern: each generation adds a receptor and unlocks additional metabolic pathways.

Semaglutide (TRT only): Appetite suppression. You eat less. ~15% weight loss.

Tirzepatide (TRT + GIP): Appetite suppression plus enhanced insulin sensitivity and fat metabolism. You eat less and your body processes fat more efficiently. ~22% weight loss.

Retatrutide (TRT + GIP + Glucagon): All of the above, plus increased energy expenditure. You eat less, process fat better, and burn more calories at rest. ~30% weight loss.

The glucagon component is the key differentiator. Glucagon signals the body to increase metabolic rate — essentially telling your cells to burn more fuel. The challenge Lilly solved was balancing this with glucose control (glucagon can raise blood sugar), which the TRT and GIP components help counteract.

What 71 lbs Means in the Real World

Clinical percentages can be abstract. Here's what 30% body weight loss looks like across different starting weights:

For context, this level of weight loss — 30% of total body weight — is comparable to what gastric sleeve surgery achieves. For patients who have considered bariatric surgery but want to avoid the procedure, retatrutide may represent a meaningful alternative once approved.

Weight loss at this magnitude also produces compounding metabolic benefits: reduced cardiovascular risk, improved insulin sensitivity, lower blood pressure, decreased joint stress, and better sleep quality. The clinical benefits of 30% weight loss extend far beyond appearance.

Comparison to Semaglutide and Tirzepatide

One important caveat: these trials weren't run head-to-head. Different patient populations, trial durations, and protocols make direct comparisons imperfect. But the magnitude of difference is large enough that most researchers consider retatrutide meaningfully superior in terms of weight loss.

What to Do While Waiting for Retatrutide

Retatrutide won't be FDA-approved until late 2026 at the earliest, and more likely 2027. If you have weight loss goals you want to address now, tirzepatide is the strongest available option — producing ~22% body weight loss with a well-established safety profile.

Compounded tirzepatide is available through telehealth providers at $249–399/month, making it accessible without insurance coverage. Starting tirzepatide now doesn't preclude switching to retatrutide when it's approved — the transition would be straightforward under medical guidance.